Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
Số trang: 14
Loại file: pdf
Dung lượng: 2.38 MB
Lượt xem: 9
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differentiate patients who respond to chemotherapy and bevacizumab, and to assess if select proteins correlate with patient survival.
Nội dung trích xuất từ tài liệu:
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
Nội dung trích xuất từ tài liệu:
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Colorectal cancer Metastatic disease Progression free survival Metastatic colorectal cancer Overall survivalGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 171 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 118 0 0 -
12 trang 93 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 43 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 37 0 0